Alembic Pharmaceuticals has received final USFDA approval for its Diltiazem Hydrochloride Extended-Release Capsules, used for treating hypertension and chronic stable angina. The capsules have an estimated market size of $28.2 million.
Alembic Pharmaceuticals has received final USFDA approval for its Diltiazem Hydrochloride Extended-Release Capsules, used for treating hypertension and chronic stable angina. The capsules have an estimated market size of $28.2 million.